The state of the hunt:AstraZeneca commenced a U.S. Phase 3 trial of its AZD1222 vaccine candidate.
Sanofi/GSK launched the first human trials of their investigational adjuvanted vaccine.
Germany, Japan and Norway joined the COVAX Facility, which now has commitments from 78 upper- and upper-middle-income countries.
Phase 3 candidates:
AstraZeneca’s AZD1222 vaccine entered a United States-based Phase 3 trial targeting 30,000…